Catalyst Intel Subscribe

Trial results

$OBX — amsoki-cel

Obsidian Therapeutics, Inc. (OBX) amsoki-cel: trial results in Immune checkpoint inhibitor-resistant advanced or metastatic melanoma, 2027.

Research by Catalyst Intel

The catalyst

"We remain on track to complete enrollment in the registration-enabling cohort by the end of the first quarter of 2027 and report topline data by year-end 2027."

— Obsidian Therapeutics, 8-K filed 2026-11-12 · the filing. Checked word for word against the stored document when this page was built; a sentence that did not check out would not be here.

Event id
OBX-AMSOKICEL-2026
Company
Obsidian Therapeutics, Inc.
Kind
Trial results
Indication
Immune checkpoint inhibitor-resistant advanced or metastatic melanoma
Window
2027-01-01 – 2027-12-31
Status
dropped

The bar

No bar has been published for this event yet.

Verdicts

No verdict has been published for this event yet.